Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador

dc.contributorGomez Contreras, María Camila [0001664780]
dc.contributorAlbarracín Ruiz, María José [0001649451]
dc.contributorCano Rosales, Diana Jimena [0000947237]
dc.contributorGomez Contreras, María Camila [0000-0003-0542-4622]
dc.contributorBernal Alarcón, Diego Nicolás [0000-0003-2072-9731]
dc.contributorCano Rosales, Diana Jimena [0000-0002-7090-5142]
dc.contributorSemilleros de Investigación UNAB
dc.creatorGomez Contreras, María Camila
dc.creatorSguerra Bergsneider, María Paula
dc.creatorEstupiñan Dueñas, Lizeth Idaly
dc.creatorBernal Alarcón, Diego Nicolás
dc.creatorCastañeda Saavedra, Stefania de los Ángeles
dc.creatorAlbarracin Ruiz, Maria Jose
dc.creatorCano Rosales, Diana Jimena
dc.date.accessioned2023-09-05T19:32:43Z
dc.date.accessioned2023-09-06T15:32:59Z
dc.date.available2023-09-05T19:32:43Z
dc.date.available2023-09-06T15:32:59Z
dc.date.created2023-09-05T19:32:43Z
dc.date.issued2018-11
dc.identifierISSN 2344-7079
dc.identifierhttp://hdl.handle.net/20.500.12749/21674
dc.identifierinstname:Universidad Autónoma de Bucaramanga - UNAB
dc.identifierreponame:Repositorio Institucional UNAB
dc.identifierrepourl:https://repository.unab.edu.co
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8682234
dc.description.abstractLa enfermedad pulmonar obstructiva crónica (EPOC) es una enfermedad común, prevenible y tratable, con alta carga de morbimortalidad y gran uso de recursos en salud, que se caracteriza por síntomas respiratorios persistentes y limitaciónen el tracto respiratorio secundario. Se reportó como la cuarta causa de muerte en el mundo en el año 2010 y en Colombia como la quinta causa de mortalidad prematura, contribuyendo en gran parte a años de vida perdidos por enfermedad. En pacientes con EPOC, la respuesta inflamatoria generada por mediadores proinflamatorios que infiltran el epitelio aéreo promueven estrés oxidativo que ocasiona el compromiso de la vía aérea cuyas manifestaciones clínicas son el broncoespasmo, edema y persistencia de la inflamación local. El estrés oxidativo generado es un factor determinante en la progresión de la enfermedad, interviene crónicamente en la inflamación bronquial y parenquimatosa pulmonar; se han descrito intervenciones con el fin de disminuirlo como el suplemento de antioxidantes sintéticos o dietéticos y la modificación de factores ambientales que promueven la oxidación como el Zinc. Existe controversia sobre la influencia de los niveles de zinc en pacientes con enfermedades respiratorias. La investigación se ha centrado en pacientes asmáticos y se ha estudiado en menor proporción en los pacientes con EPOC, en los cuales la evidencia sobre el zinc es mínima y no hay un consenso que separe el manejo dietario con suplementos como el zinc en los pacientes con fenotipo exacerbador frecuente versus el fenotipo no exacerbador. A través de este estudio, se propone medir marcadores inflamatorios, se propone medir marcadores inflamatorios de estrés oxidativo y de sustancias relacionadas con la inflamación en los pacientes con EPOC, para determinar el impacto de estos niveles séricos en las exacerbaciones en nuestra población a estudio.
dc.languagespa
dc.publisherUniversidad Autónoma de Bucaramanga UNAB
dc.publisherFacultad Ciencias de la Salud
dc.publisherPregrado Medicina
dc.publisherSistema de Investigación SIUNAB
dc.relationGeneración Creativa : Encuentro de Semilleros de Investigación UNAB
dc.relationhttp://hdl.handle.net/20.500.12749/14242
dc.relation1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 Mar;195(5):557–82.
dc.relation2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012 Dec;380(9859):2095–128.
dc.relation3. WHO | The global burden. WHO [Internet]. 2010 [cited 2017 Sep 21]; Available from: http://who.int/substance_abuse/facts/global_burden/en/
dc.relation4. Partridge MR, Miravitlles M, Stahl E, Karlsson N, Svensson K, Welte T. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J [Internet]. 2010 Jul 1 [cited 2017 Sep 21];36(1):96–104. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19897551
dc.relation5. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J [Internet]. 2009 May 1 [cited 2017 Sep 21];33(5):1165–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19407051
dc.relation6. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet [Internet]. 2007 Sep 1 [cited 2017 Sep 21];370(9589):797–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17765529
dc.relation7. Rerksuppaphol S, Rerksuppaphol L. Zinc Supplementation in Children with Asthma Exacerbation. Pediatr Rep [Internet]. 2016 Nov 17 [cited 2017 Sep 21];8(4):6685. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28058103
dc.relation8. Riccioni G, D’Orazio N. The role of selenium, zinc and antioxidant vitamin supplementation in the treatment of bronchial asthma: adjuvant therapy or not? Expert Opin Investig Drugs [Internet]. 2005 Sep 22 [cited 2017 Sep 21];14(9):1145–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16144498
dc.relation9. Guo C-H, Liu P-J, Lin K-P, Chen P-C. Nutritional supplement therapy improves oxidative stress, immune response, pulmonary function, and quality of life in allergic asthma patients: an open-label pilot study. Altern Med Rev [Internet]. 2012 Mar [cited 2017 Sep 19];17(1):42–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22502622
dc.relation10. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet [Internet]. 2012 Dec 15 [cited 2017 Sep 14];380(9859):2197–223. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23245608
dc.relation11. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet [Internet]. 2004 Aug [cited 2017 Sep 14];364(9434):613– 20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15313363
dc.relation12. Raherison C, Girodet P-O. Epidemiology of COPD. Eur Respir Rev [Internet]. 2009 [cited 2017 Sep 13];18(114). Available from: http://err.ersjournals.com/content/18/114/213#T2
dc.relation13. Menezes AMB, Perez-Padilla R, Jardim JRB, Muiño A, Lopez MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet (London, England). 2005 Nov;366(9500):1875–81.
dc.relation14. Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133(2):343–9.
dc.relation15. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med [Internet]. 2010 Sep 16 [cited 2017 Sep 14];363(12):1128– 38. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0909883
dc.relation16. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebocontrolled TORCH study. Respir Res [Internet]. 2009 Dec 30 [cited 2017 Sep 14];10(1):59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19566934
dc.relation17. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet [Internet]. 2009 Oct 3 [cited 2017 Sep 14];374(9696):1171–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19716598
dc.relation18. Soler-Cataluna JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax [Internet]. 2005 Nov 1 [cited 2017 Sep 14];60(11):925–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16055622
dc.relation19. Pauwels RA, Löfdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking. N Engl J Med. 1999 Jun;340(25):1948–53.
dc.relation20. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (London, England). 1999 May;353(9167):1819–23.
dc.relation21. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med [Internet]. 2008 Oct 9 [cited 2017 Sep 12];359(15):1543–54. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0805800
dc.relation22. O’Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6).
dc.relation23. O’Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, et al. Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest. 2006 Sep;130(3):647–56.
dc.relation24. Zalewski PD, Truong-Tran AQ, Grosser D, Jayaram L, Murgia C, Ruffin RE. Zinc metabolism in airway epithelium and airway inflammation: Basic mechanisms and clinical targets. A review. Pharmacol Ther. 2005;105(2):127–49.
dc.relation25. Zalewski PD. Zinc metabolism in the airway: basic mechanisms and drug targets. Curr Opin Pharmacol. 2006;6(3):237–43.
dc.relation26. Daga MK, Chhabra R, Sharma B, Mishra TK. Effects of exogenous vitamin E supplementation on the levels of oxidants and antioxidants in chronic obstructive pulmonary disease. J Biosci [Internet]. 2003 Feb [cited 2017 Sep 19];28(1):7–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12682418
dc.relation27. Kondo T, Tagami S, Yoshioka A, Nishimura M, Kawakami Y. Current smoking of elderly men reduces antioxidants in alveolar macrophages. Am J Respir Crit Care Med [Internet]. 1994 Jan [cited 2017 Sep 19];149(1):178–82. Available from: http://www.atsjournals.org/doi/abs/10.1164/ajrccm.149.1.8 111579
dc.relation28. Di Toro R, Galdo Capotorti G, Gialanella G, Miraglia del Giudice M, Moro R, Perrone L. Zinc and copper status of allergic children. Acta Paediatr Scand [Internet]. 1987 Jul [cited 2017 Sep 19];76(4):612–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3630679
dc.relation29. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Garg ML. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids [Internet]. 2000 Sep [cited 2017 Sep 19];35(9):967– 74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11026617
dc.relation30. el-Kholy MS, Gas Allah MA, el-Shimi S, el-Baz F, elTayeb H, Abdel-Hamid MS. Zinc and copper status in children with bronchial asthma and atopic dermatitis. J Egypt Public Health Assoc [Internet]. 1990 [cited 2017 Sep 19];65(5–6):657–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2134100
dc.relation31. Kadrabová J, Mad’aric A, Podivínsky F, Gazdík F, Ginter F. Plasma zinc, copper and copper/zinc ratio in intrinsic asthma. J Trace Elem Med Biol [Internet]. 1996 Apr [cited 2017 Sep 19];10(1):50–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8793823
dc.relation32. Kirkil G, Hamdi Muz M, Seçkin D, Sahin K, Küçük O. Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease. Respir Med [Internet]. 2008;102(6):840–4. Available from: www.pubmed.gov
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rightsAbierto (Texto Completo)
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.sourceGomez, M. C., et al. (2018). Niveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador. Recuperado de: http://hdl.handle.net/20.500.12749/21674
dc.titleNiveles De Zinc En Pacientes Con Epoc Fenotipo Exacerbador
dc.typeConference


Este ítem pertenece a la siguiente institución